secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001558370-22-008110
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution
--------------------------------------------------------------------------------

- Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.
- Royalty revenue of $13.8M from Rayner's OMIDRIA sales ($27.7M, all U.S.); up from $21.1M prior Omeros net sales.
- Cash, equivalents, short-term investments $142.2M at March 31, 2022; down $15M from Dec 2021.
- FDA denied narsoplimab BLA (TA-TMA); Omeros plans formal dispute resolution within weeks.
- Enrollment expected summer 2022 for Phase 1b OMS906 (PNH) and Phase 1 OMS1029 (long-acting MASP-2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/0001558370-22-008110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/omer-20220510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer